Please provide your email address to receive an email when new articles are posted on . SAN DIEGO — Oral vancomycin safely induced and maintained remission of ulcerative colitis among a subset of ...
Amneal is voluntarily recalling four lots of Vancomycin Hydrochloride for Oral Solution, 250 mg/5 mL packaged in 80 mL, 150 mL or 300 mL pack sizes, to the consumer level. Some bottles may have been ...
BAUDETTE, Minn., Sept. 11, 2019 /PRNewswire/ -- ANI Pharmaceuticals, Inc. ("ANI") (Nasdaq: ANIP) today announced the launch of Vancomycin HCl for Oral Solution, 250mg per 5mL (the generic equivalent ...
During the manual bottle filling stage of manufacturing, some bottles may have been overfilled resulting in an over potent dosing regimen. Amneal Pharmaceuticals, LLC is voluntarily recalling 4 lots ...
Vancomycin is indicated to treat enterocolitis caused by Staphylococcus aureus and antibiotic-associated pseudomembranous colitis caused by C. difficile. ANI Pharmaceuticals announced that the Food ...
"Based on our pilot data, OV [oral vancomycin] is a useful option for a subgroup of mildly active UC/IBDU patients," the authors of the study concluded. "While systematic OV use before biologic or ...
WILMINGTON, Mass., April 2, 2018 /PRNewswire/ -- CutisPharma announced today the commercial launch of FIRVANQ™ (vancomycin hydrochloride) for oral solution, for the treatment of Clostridium difficile ...
The FDA on Monday granted approval to CutisPharma’s drug Firvanq to treat Clostridium difficile-associated diarrhea and Staphylococcus aureus-associated intestinal inflammation (enterocolitis). Here ...
Azurity Pharmaceuticals, Inc. — a pioneer drug company that markets its FDA-approved oral vancomycin hydrochloride solution, FIRVANQ® — has sued Edge Pharma, LLC, an outsourcing facility operating ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results